MESA LABORATORIES INC (MLAB) — insider trading
Health Care · NASDAQ
MESA LABORATORIES INC (MLAB) has 54 reported SEC Form 4 insider transactions in our data, including 2 open-market purchases and 7 open-market sales among the most recent 54 (latest 2026-09-09).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-09 | Sullivan John James | Director | Grant / award / vesting (derivative) | 1,774 | — | $0 | Form 4 |
| 2026-09-09 | Tripeny R Tony | Director | Grant / award / vesting (derivative) | 1,774 | — | $0 | Form 4 |
| 2026-09-09 | Ladiwala Shiraz Shabanali | Director | Grant / award / vesting (derivative) | 2,510 | — | $0 | Form 4 |
| 2026-09-09 | Hall Shannon | Director | Grant / award / vesting (derivative) | 1,774 | — | $0 | Form 4 |
| 2026-09-09 | Capone Mark Christopher | Director | Grant / award / vesting (derivative) | 2,423 | — | $0 | Form 4 |
| 2026-08-15 | Sullivan John James | Director | Option exercise / conversion (derivative) | 2,784 | — | $0 | Form 4 |
| 2026-08-15 | Sullivan John James | Director | Option exercise / conversion | 2,784 | — | $0 | Form 4 |
| 2026-08-15 | Tripeny R Tony | Director | Option exercise / conversion (derivative) | 2,784 | — | $0 | Form 4 |
| 2026-08-15 | Tripeny R Tony | Director | Option exercise / conversion | 2,784 | — | $0 | Form 4 |
| 2026-08-15 | Hall Shannon | Director | Option exercise / conversion (derivative) | 2,784 | — | $0 | Form 4 |
| 2026-08-15 | Hall Shannon | Director | Option exercise / conversion | 2,784 | — | $0 | Form 4 |
| 2026-08-15 | Ladiwala Shiraz Shabanali | Director | Option exercise / conversion (derivative) | 3,810 | — | $0 | Form 4 |
| 2026-08-15 | Ladiwala Shiraz Shabanali | Director | Option exercise / conversion | 3,810 | — | $0 | Form 4 |
| 2026-08-15 | Alltoft Jennifer Sadie | Director | Option exercise / conversion (derivative) | 2,784 | — | $0 | Form 4 |
| 2026-08-15 | Alltoft Jennifer Sadie | Director | Option exercise / conversion | 2,784 | — | $0 | Form 4 |
| 2026-08-15 | Capone Mark Christopher | Director | Option exercise / conversion (derivative) | 2,784 | — | $0 | Form 4 |
| 2026-08-15 | Capone Mark Christopher | Director | Option exercise / conversion | 2,784 | — | $0 | Form 4 |
| 2026-08-13 | Tripeny R Tony | Director | Open-market purchase | 900 | $113.69 | $102.3K | Form 4 |
| 2026-08-13 | Kadia Siddhartha | Officer (President and CEO) | Open-market purchase | 7,093 | $112.80 | $800.1K | Form 4 |
| 2026-08-13 | Sullivan John James | Director | Open-market sale | 7,093 | $112.80 | $800.1K | Form 4 |
| 2026-06-22 | Sakys John | Officer (CFO) | Open-market sale | 2,827 | $89.50 | $253.0K | Form 4 |
| 2026-06-22 | Archbold Brian David | Officer (SVP Operations) | Open-market sale | 2,516 | $89.50 | $225.2K | Form 4 |
| 2026-06-22 | Crennen Lyndsey Elizabeth | Officer (CAO) | Open-market sale | 442 | $89.50 | $39.6K | Form 4 |
| 2026-06-18 | Sakys John | Officer (CFO) | Option exercise / conversion (derivative) | 2,756 | — | $0 | Form 4 |
| 2026-06-18 | Sakys John | Officer (CFO) | Option exercise / conversion (derivative) | 1,036 | — | $0 | Form 4 |
| 2026-06-18 | Sakys John | Officer (CFO) | Grant / award / vesting | 2,282 | $95.10 | $217.0K | Form 4 |
| 2026-06-18 | Sakys John | Officer (CFO) | Option exercise / conversion | 2,756 | $95.10 | $262.1K | Form 4 |
| 2026-06-18 | Sakys John | Officer (CFO) | Option exercise / conversion | 1,036 | $95.10 | $98.5K | Form 4 |
| 2026-06-18 | Archbold Brian David | Officer (SVP Operations) | Option exercise / conversion (derivative) | 2,480 | — | $0 | Form 4 |
| 2026-06-18 | Archbold Brian David | Officer (SVP Operations) | Option exercise / conversion (derivative) | 844 | — | $0 | Form 4 |
| 2026-06-18 | Archbold Brian David | Officer (SVP Operations) | Grant / award / vesting | 1,859 | $95.10 | $176.8K | Form 4 |
| 2026-06-18 | Archbold Brian David | Officer (SVP Operations) | Option exercise / conversion | 2,480 | $95.10 | $235.8K | Form 4 |
| 2026-06-18 | Archbold Brian David | Officer (SVP Operations) | Option exercise / conversion | 844 | $95.10 | $80.3K | Form 4 |
| 2026-06-18 | Crennen Lyndsey Elizabeth | Officer (CAO) | Option exercise / conversion (derivative) | 368 | — | $0 | Form 4 |
| 2026-06-18 | Crennen Lyndsey Elizabeth | Officer (CAO) | Option exercise / conversion (derivative) | 233 | — | $0 | Form 4 |
| 2026-06-18 | Crennen Lyndsey Elizabeth | Officer (CAO) | Option exercise / conversion (derivative) | 125 | — | $0 | Form 4 |
| 2026-06-18 | Crennen Lyndsey Elizabeth | Officer (CAO) | Grant / award / vesting | 263 | $95.10 | $25.0K | Form 4 |
| 2026-06-18 | Crennen Lyndsey Elizabeth | Officer (CAO) | Option exercise / conversion | 368 | $95.10 | $35.0K | Form 4 |
| 2026-06-18 | Crennen Lyndsey Elizabeth | Officer (CAO) | Option exercise / conversion | 233 | $95.10 | $22.2K | Form 4 |
| 2026-06-18 | Crennen Lyndsey Elizabeth | Officer (CAO) | Option exercise / conversion | 125 | $95.10 | $11.9K | Form 4 |
| 2026-06-16 | Sakys John | Officer (CFO) | Open-market sale | 1,223 | $101.27 | $123.8K | Form 4 |
| 2026-06-16 | Crennen Lyndsey Elizabeth | Officer (CAO) | Open-market sale | 118 | $101.27 | $11.9K | Form 4 |
| 2026-06-16 | Archbold Brian David | Officer (SVP Operations) | Open-market sale | 1,151 | $101.27 | $116.6K | Form 4 |
| 2026-06-15 | Sakys John | Officer (CFO) | Grant / award / vesting (derivative) | 8,416 | — | $0 | Form 4 |
| 2026-06-15 | Sakys John | Officer (CFO) | Option exercise / conversion (derivative) | 2,717 | — | $0 | Form 4 |
| 2026-06-15 | Sakys John | Officer (CFO) | Expiration of short derivative position (derivative) | 3,951 | — | $0 | Form 4 |
| 2026-06-15 | Sakys John | Officer (CFO) | Option exercise / conversion | 2,717 | $104.08 | $282.8K | Form 4 |
| 2026-06-15 | Archbold Brian David | Officer (SVP Operations) | Grant / award / vesting (derivative) | 4,328 | — | $0 | Form 4 |
| 2026-06-15 | Archbold Brian David | Officer (SVP Operations) | Option exercise / conversion (derivative) | 2,454 | — | $0 | Form 4 |
| 2026-06-15 | Archbold Brian David | Officer (SVP Operations) | Expiration of short derivative position (derivative) | 1,780 | — | $0 | Form 4 |
| 2026-06-15 | Archbold Brian David | Officer (SVP Operations) | Option exercise / conversion | 2,454 | $104.08 | $255.4K | Form 4 |
| 2026-04-14 | Kadia Siddhartha | Officer (President and CEO) | Grant / award / vesting (derivative) | 35,236 | — | $0 | Form 4/A |
| 2026-04-14 | Kadia Siddhartha | Officer (President and CEO) | Grant / award / vesting (derivative) | 34,807 | — | $0 | Form 4 |
| 2009-09-09 | Alltoft Jennifer Sadie | Director | Grant / award / vesting (derivative) | 1,774 | — | $0 | Form 4 |
Ask the chat about MLAB's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: MESA LABORATORIES INC (MLAB).
Last updated 2026-09-09 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.